JPRN-jRCT2080223256已完成2 期
A Phase 2 to Evaluate the Dose-Response Relationship and Safety of JTT-751 in Patients with Iron Deficiency Anemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 147
研究概览
简要总结
The efficacy and safety results suggested that JTT-751 was expected to be clinically useful for patients with iron deficiency anemia.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 64age old（—）
- 性别
- All
入选标准
- •Iron deficiency anemia
- •Hemoglobin level of= > 7.0 g/dL and < 11.0 g/d
排除标准
- •Anemia caused by other than iron deficiency
- •Serum phosphate < 2.5 mg/dL
- •Uncontrollable treatment potentially affecting bleeding in patients with bleeding lesion
研究者
相似试验
已完成
2 期
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection FractionChronic Heart FailureNCT06017609Akros Pharma Inc.314
已完成
2 期
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsDyslipidemiaNCT00688558Akros Pharma Inc.92
已完成
2 期
Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) LevelsDyslipidemiaNCT00689442Akros Pharma Inc.105
终止
3 期
Efficacy and Safety of JT001 (VV116) Compared With FavipiravirModerate to Severe COVID-19NCT05279235Shanghai Vinnerna Biosciences Co., Ltd.290
撤回
2 期
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT03789643Akros Pharma Inc.